BioSpace

ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3

A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.

By BioSpace

1 min read
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights